In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
All content for Divergent States is the property of Divergent States and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
How Politics Could Derail Psychedelic Medicine — Again
Divergent States
38 minutes
2 months ago
How Politics Could Derail Psychedelic Medicine — Again
History shows politics can make or break psychedelic medicine, will we repeat the 1960s backlash, or finally move forward? In this episode of Divergent States, we explore the uneasy intersection of psychedelics and politics. MDMA remains a Schedule I drug—classified as dangerous with no medical use—while at the same time advancing through FDA Phase III trials. This contradiction highlights the limbo psychedelics face today: criminalized on one side, medicalized on the other. We revisit ...
Divergent States
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
